Interferon β-1a and β-1b for patients with multiple sclerosis: updates to current knowledge.

Area of Science:

• Neurology
• Immunology
• Pharmacology

Background:

• Multiple sclerosis (MS) is a chronic, incurable neurological disease.
• Interferon beta (IFNβ) has been a primary therapeutic agent for MS for many years.
• Various IFNβ formulations exist, offering different dosing frequencies and exposure levels.

Purpose of the Study:

• To review current and emerging data on the efficacy and safety of IFNβ in MS treatment.
• To evaluate the impact of different IFNβ dosing strategies on clinical and imaging outcomes.
• To assess the overall risk-benefit profile of IFNβ therapy in managing MS.

Main Methods:

• Comprehensive review of decades of clinical trial data and real-world evidence for IFNβ in MS.
• Analysis of efficacy endpoints including relapse rates, disability progression, and MRI lesion outcomes.
• Evaluation of safety data and adverse event profiles associated with different IFNβ exposure levels.

Main Results:

• High-dose and/or high-frequency IFNβ regimens (IFNβ-1a, IFNβ-1b) show significant benefits compared to lower exposure levels.
• Demonstrated improvements in relapse rates, disability progression, and MRI-detected disease activity.
• IFNβ therapy is generally well-tolerated, with a well-characterized safety profile; adverse events are typically mild and manageable.

Conclusions:

• Interferon beta is a foundational and well-understood treatment for multiple sclerosis, supported by extensive clinical and real-world data.
• Higher-dose/frequency IFNβ regimens are associated with potentially better long-term outcomes in MS management.
• The established safety profile and manageable adverse events contribute to IFNβ's continued role in MS therapy.